MOLECULAR PARTNERS AG (MOLN): Price and Financial Metrics
MOLN Price/Volume Stats
Current price | $3.78 | 52-week high | $7.32 |
Prev. close | $3.87 | 52-week low | $3.32 |
Day low | $3.75 | Volume | 500 |
Day high | $3.80 | Avg. volume | 11,957 |
50-day MA | $3.95 | Dividend yield | N/A |
200-day MA | $4.83 | Market Cap | 137.47M |
MOLN Stock Price Chart Interactive Chart >
MOLECULAR PARTNERS AG (MOLN) Company Bio
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials.
Latest MOLN News From Around the Web
Below are the latest news stories about MOLECULAR PARTNERS AG that investors may wish to consider to help them evaluate MOLN as an investment opportunity.
Retail investors account for 43% of Molecular Partners AG's (VTX:MOLN) ownership, while hedge funds account for 33%Key Insights Significant control over Molecular Partners by retail investors implies that the general public has more... |
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor ConferencesZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place from January 8-11, 2024 in San Francisco, CA. In addition, members of Molecular Partners’ leadership team will participate in upcoming investor events in Switzerland during |
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingInitial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range threeMP0533 monotherapy continues to demonstrate an acceptable safety profile across the first four dosing cohorts, with no dose-limiting toxicities observed Phase 1/2a trial remains ongoing with patients being enrolled in fifth of seven planned dose-escalation cohorts ZURICH-S |
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing toxicities seen with other targeted modalities Review includes differentiated mechanisms of action including tumor-localized activation, avidity-driven selectivity and novel SWITCH-DARPin approach ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech com |
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
MOLN Price Returns
1-mo | 13.86% |
3-mo | N/A |
6-mo | N/A |
1-year | -42.99% |
3-year | N/A |
5-year | N/A |
YTD | -9.57% |
2023 | -36.18% |
2022 | -65.85% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...